Danaher Corporation provided revised guidance for fourth quarter 2020. For the quarter, core revenue growth including Cytiva is expected to be above the Company's previously announced guidance, driven primarily by better performance in its Life Sciences and Diagnostics segments, and estimated revenues increased approximately 38.5% year-over-year.